Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Item
http://www.wikidata.org/entity/Q33839177
Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized cAfatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.Combinational therapy of crizotinib and afatinib for malignant pleural mesothelioma.Afatinib in squamous cell carcinoma of the head and neck.Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.[Treatment of head and neck squamous cell carcinoma recurrences and distant metastases: Highlights of the ASCO Meeting 2015].Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma.
P2860

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Item
http://www.wikidata.org/entity/Q33839177
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
type
label
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
prefLabel
Rationale and design of LUX-He ...... d after platinum-based therapy
@ast
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Rationale and design of LUX-He ...... d after platinum-based therapy
@en
P2093
P2860
P2888
P304
P31
P356
P407
P478
P50
P577
P5875
P6179
P698
P921
P932